Dose optimization: an individualized treatment strategy for chronic myeloid leukemia.
10.3760/cma.j.issn.0253-2727.2022.05.017
- Author:
Yi Lin CHEN
1
;
Jing ZOU
1
;
Yan Li ZHANG
2
;
Wei Ming LI
1
Author Information
1. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
2. Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents/therapeutic use*;
Humans;
Imatinib Mesylate/therapeutic use*;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*
- From:
Chinese Journal of Hematology
2022;43(5):436-440
- CountryChina
- Language:Chinese
